Abstracts tagged "clinical trial"

Abstract Number: 1517 • ACR Convergence 2023
Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients
Baran Gunes¹, Lucy Duran Camacho¹, Shawn Cowper², Gauri Panse², Elizabeth Bundschuh³, Alyssa Williams⁴, Nicolas Page⁵, Mary Karns⁶, Kathleen Aren⁶, Niki Pradhan⁷, Elana Bernstein⁸, Sarah Fantus⁹, Elizabeth Volkmann¹⁰, Heather Bukiri¹⁰, Chase Correia¹¹, Francis Wilson¹, Seamus Mawe¹², J. Matthew Mahoney¹³, Monique Hinchcliff¹⁴ and Rui Wang¹⁵, ¹Yale University School of Medicine, New Haven, CT, ²Yale School of Medicine - Dermatopathology, New Haven, CT, ³Yale University School of Medicine, New York, NY, ⁴Yale University School of Medicine, Winchester, MA, ⁵Yale University School of Medicine, Salem, CT, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷Columbia University Irving Medical Center, New York, NY, ⁸Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁹Kansas City Physician Partners- Center for Rheumatic Disease, Kansas City, MO, ¹⁰University of California Los Angeles, Los Angeles, CA, ¹¹Riverside Medical Group, Hampton, VA, ¹²The Jackson Laboratory, Bar Harbor, ME, ¹³Jackson Laboratory, Bar Harbor, ME, ¹⁴Yale School of Medicine, Westport, CT, ¹⁵Sanofi, Cambridge, MA
Background/Purpose: We previously published a proof-of-principle study demonstrating the potential utility of computer vision (Deep Neural Network/DNN) methods applied to stained skin biopsy sections from…
Abstract Number: 1992 • ACR Convergence 2023
Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials
Claire Miller¹, Matthew Baker², Peter Alexandersen³, Alejandro Mondragón¹, Ida Sofie Adrian¹, Morten Karsdal⁴, Jeppe Andersen⁵ and Asger Bihlet¹, ¹NBCD, Soeborg, Denmark, ²Stanford University, Menlo Park, CA, ³Sanos Clinics, Gandrup, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Sanos Group, Soeborg, Denmark
Background/Purpose: Patients with knee osteoarthritis are often overweight and suffer from comorbidities, which are frequently treated pharmacologically. Our understanding of the potential disease-modifying and/or symptom-modifying…
Abstract Number: 2249 • ACR Convergence 2023
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Dafna Gladman¹, Laura Coates², Maarten de Wit³, Alexis R Ogdie⁴, Ana-Maria Orbai⁵, Barbara Ink⁶, Vanessa Taieb⁷, Jérémy Lambert⁸ and Laure Gossec⁹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Irigny, France, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…
Abstract Number: 2490 • ACR Convergence 2023
Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
Junna Ye¹, Yijun You², Zhuochao Zhou², Jingyi Wu², Fan wang² and Chengde Yang², ¹Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…
Abstract Number: 0444 • ACR Convergence 2023
Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis
Chie Watai¹, Kazuoki Tsuruda², Yoshinori Tsumura¹ and Daisuke Tasaki¹, ¹Teijin Pharma Limited, Chiyoda City Tokyo, Japan, ²Teijin America, Inc., Sausalito, CA
Background/Purpose: TCK-276 is a highly potent, orally active, and selective cyclin dependent kinase 4/6 (CDK4/6) inhibitor that is in development as a novel synthetic disease…
Abstract Number: 0776 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
Alan Kivitz¹, Liliana Sedova², Melvin Churchill³, Roshan Kotha⁴, Atul Singhal⁵, Alexander Torres⁶, Guillermo Valenzuela⁷, Sarah Whelan⁸, Thomas Dumortier⁹, Xuan Zhu¹⁰, Ruvie Martin¹⁰ and Luminita Pricop¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institute of Rheumatology, Prague, Czech Republic, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Sharp Community Medical Group, La Mesa, CA, ⁵Southwest Arthritis Research Group, Mesquite, TX, ⁶Highlands Advanced Rheumatology and Arthritis Center, Avon Park, FL, ⁷Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁸Novartis Ireland Ltd, Dublin, Ireland, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: To investigate the long-term efficacy, safety, and tolerability of intravenous (IV) secukinumab (SEC) in patients with active psoriatic arthritis (PsA) through 52 weeks.Methods: INVIGORATE-2…
Abstract Number: 1183 • ACR Convergence 2023
CoLchicine for Treatment of OsteoArthritis of the Knee—Updated Data from a Double-blind, Placebo-controlled Trial
Katherine Tse¹, Roni Meidan², Michael Toprover³, David Wei², Nicole Leung⁴, Maryfe Coronel², Julia Cai², Aryan Jain², maria lessa², Renata La Rocca Vieira², Svetlana Krasnokutsky Samuels², Michael Pillinger⁵ and Jonathan Samuels⁶, ¹NYU Langone, New York, NY, ²NYU Langone Helath, New York, NY, ³New York University Langone Health, New York, NY, ⁴New York University Langone Hospital, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Langone, Rye Brook, NY
Background/Purpose: Knee osteoarthritis (OA) has a probable inflammatory role for IL-1b. The presence of calcium and urate crystals may contribute to OA by activating the…
Abstract Number: 1429 • ACR Convergence 2023
Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Carlo Selmi¹, Fausto Salaffi², Sibel Aydin³, Enrique Soriano⁴, Emmanouil Rampakakis⁵, Mohamed Sharaf⁶, Miriam Zimmermann⁷, Frederic Lavie⁸, Peter Nash⁹ and Philip J. Mease¹⁰, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ²Polytechnic University of Marche, Department of Clinical and Molecular Sciences, Carlo Urbani Hospital, Ancona, Italy, ³Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁷Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹School of Medicine, Griffith University, Brisbane, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: PsA-5Ts is a simple multidimensional composite measure, assessing pain, fatigue, physical function, skin problems, and depression, recently developed to measure overall health in PsA…
Abstract Number: 1525 • ACR Convergence 2023
Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis
Alison Fernandes, Ashraf El-Meanawy and ME Csuka, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Calcinosis is a common complication of systemic sclerosis (SSc), though effective treatment options are limited. Of the several medical therapies that have been employed…
Abstract Number: 2003 • ACR Convergence 2023
Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis
Ruban Dhaliwal¹, John Boxberger², Yamei Wang², Bruce Mitlak², Ludovic Humbert³ and Neil Binkley⁴, ¹Massachusetts General Hospital, Boston, MA, ²Radius Health, Inc., Boston, MA, ³3D-Shaper Medical, Barcelona, Spain, ⁴University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI
Background/Purpose: Abaloparatide (ABL) increases BMD in men with osteoporosis. In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) trial, DXA-measured BMD change with…
Abstract Number: 2255 • ACR Convergence 2023
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Kilian Eyerich¹, Alice B. Gottlieb², Stefano Piaserico³, Stefan Beissert⁴, Melinda Gooderham⁵, Brian Kirby⁶, Nicola Tilt⁷, Cynthia Madden⁸, Susanne Wiegratz⁹, Dirk de Cuyper¹⁰, Joseph F. Merola¹¹ and Boni Elewski¹², ¹Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Dermatology Unit, Department of Medicine, Università di Padova, Padova, Italy, ⁴Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, ⁵SKiN Centre for Dermatology, Probity Medical Research, Peterborough, ON, Canada, and Queen’s University, Kingston, ON, Canada, ⁶Elm Park and the Charles Institute, St Vincent's University Hospital, University College Dublin, Dublin, Ireland, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Morrisville, NC, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH
Background/Purpose: Psoriatic lesions in highly visible areas, including the nails, disproportionately affect patients' health‑related quality of life.[1] Here, we compare the efficacy of bimekizumab (BKZ)…
Abstract Number: 2501 • ACR Convergence 2023
Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity
Jingru Tian¹, Shuntong Kang², Dingyao Zhang³ and Qianjin Lu⁴, ¹Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Nanjing, China, ³Graduate Program in Biological and Biomedical Sciences, Yale University, New Haven, CT, ⁴Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a common multisystem autoimmune disease with chronic inflammation. Many efficacy evaluation indicators of randomized clinical trials (RCTs) for SLE…
Abstract Number: 0450 • ACR Convergence 2023
Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting
Martinus Van de Laar¹, Martijn Oude Voshaar¹, Peter ten Klooster¹, Danyta Tedjo² and celine van de laar³, ¹University of Twente, Hengelo (OV), Netherlands, ²TiH @ University of Twente, Hengelo (OV), Netherlands, ³Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
Abstract Number: 0780 • ACR Convergence 2023
Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with active psoriatic arthritis (PsA), a heterogeneous immune-mediated disease. IL-17 inhibition has…
Abstract Number: 1191 • ACR Convergence 2023
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee
Guang-Liang Jiang¹ and Feng Xu², ¹Xgene Pharmaceutical Inc., Lexington, MA, ²Xgene Pharmaceutical Inc., Altos Hills, CA
Background/Purpose: Globally osteoarthritis affects about 302 million patients, knee osteoarthritis accounts for 263 million and ranks the highest in disability and pain compared to OA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.